TENAX THERAPEUTICS INC. news, videos and press releases
For more news please use our advanced search feature.
TENAX THERAPEUTICS INC. - More news...
TENAX THERAPEUTICS INC. - More news...
- Tenax Therapeutics to Participate in the Guggenheim SMID Cap Biotech Conference
- Tenax Therapeutics Appoints Gillian Andor Vice President, Clinical Operations
- Tenax Therapeutics Reports Third Quarter 2024 Financial Results and Provides a Corporate Update
- Tenax Therapeutics to Present at the Guggenheim Healthcare Innovation Conference
- Tenax Therapeutics Reports Second Quarter 2024 Financial Results and Provides a Corporate Update
- Tenax Therapeutics Announces Closing of $100 Million Private Placement and Plans to Accelerate the Oral Levosimendan Phase 3 Program
- Tenax Therapeutics Announces Oversubscribed $100 Million Private Placement
- Tenax Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update
- Tenax Therapeutics Announces New U.S. Patent Covering the Use of Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)
- Tenax Therapeutics to Host KOL Event: “LEVEL Setting: the Scientific Rationale for Levosimendan as a Potential First Treatment for PH-HFpEF, and the Ongoing Phase 3 LEVEL Study”
- Tenax Therapeutics Provides Business and Clinical Development Updates with Full Year 2023 Financial Results
- Tenax Therapeutics to Present at the 36th Annual Roth Conference
- Tenax Therapeutics Announces Oral Presentation of Levosimendan for the Treatment of PH-HFpEF at THT 2024
- Tenax Therapeutics Announces Global License Amendment that Significantly Expands Rights to Levosimendan
- Tenax Therapeutics Announces Pricing of Approximately $9 Million Public Offering
- Tenax Therapeutics Enrolls First Patient in Phase 3 LEVEL Study Evaluating TNX-103 (Oral Levosimendan) for the Treatment of Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction (PH-HFpEF)
- Thinking about buying stock in McDonald's, Uber Technologies, Medavail, Intelligent Bio Solutions, or Tenax Therapeutics?
- Tenax Therapeutics Announces USPTO Grants Notice of Allowance for U.S. Patent Application, Significantly Broadening IP Protection for Use of Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)
- Tenax Therapeutics Announces Reverse Stock Split
- Tenax Therapeutics Announces Professor Javed Butler, M.D., M.P.H, M.B.A., joins PH-HFpEF Scientific Advisory Board
- Tenax Therapeutics Announces FDA Clearance of IND for TNX-103 (oral levosimendan) for the Treatment of Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF), Initiation of Phase 3 sites expected 2023
- Tenax Therapeutics Issued U.S. Patent for Oral Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)
- Tenax Therapeutics Achieves Major Milestone as USPTO Grants Notice of Allowance for U.S. Patent Application Covering Use of Oral Levosimendan (TNX-103) in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)
- Tenax Therapeutics Provides 2023 Business Update
- Tenax Announces Issuance of U.S. Patent Covering Use of IV Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)
- Tenax Therapeutics Announces Pricing of Approximately $15.6 Million Public Offering
- Tenax Granted Notice of Allowance for U.S. Patent Application Covering Use of IV Levosimendan in Pulmonary Hypertension with Heart Failure and Preserved Ejection Fraction (PH-HFpEF)
- Tenax Therapeutics Announces Reverse Stock Split
- Positive Data Presented at HFSA Annual Meeting Demonstrate Effects of Oral Levosimendan in Patients with Pulmonary Hypertension and Heart Failure with Preserved Ejection Fraction (PH-HFpEF)
- Tenax Therapeutics Announces the Evaluation of Strategic Alternatives
